09/09/2026
Medicareâs new GLP-1 Bridge program is creating another pathway for eligible beneficiaries to access certain weight-management medications.
The temporary program began July 1, 2026, and is scheduled to run through December 31, 2027. As of August 2026, it includes Wegovy, Foundayo and Zepbound (KwikPen only) for a $50 monthly copay. Ozempic and Mounjaro are not included.
Eligibility depends on both Medicare drug coverage and health criteria. Beneficiaries may qualify with a BMI of 35 or higher, or with a lower BMI plus certain conditions, such as prediabetes, uncontrolled high blood pressure, chronic kidney disease, certain heart conditions, or a previous heart attack or stroke.
A standalone Part D plan isnât required. Members of eligible Medicare Advantage plans with prescription drug coverage can qualify as well.
There are additional eligibility requirements and exclusions, so the best place to start is with a health care provider, who can determine whether the clinical requirements are met.
Have questions about how the GLP-1 Bridge fits with your Medicare coverage? Weâre happy to help you understand your options.